In their trials, tirzepatide (Mounjaro) produced a higher average weight loss, about 20% of total body weight at the top dose, while orforglipron (Foundayo) produced about 12%, with some patients losing up to 15%
Clinical trials of tirzepatide extended up to 72 weeks, with continued weight loss throughout the study period
Here is what you can expect to be included and example responses for an initial prescription
This is interesting, Stuart as it reminds me of a conversation I recently had on a diving trip
In conclusion, the market needs diabetes drugs that are high-quality, low-cost, affordable, and have multiple effects to improve patients metabolic syndrome and quality of life
Some researchers theorize that TB-500 could support hair follicle regeneration, though direct evidence is limited